Contrasting Evoke Pharma (NASDAQ:EVOK) & Northwest Biotherapeutics (OTCMKTS:NWBO)

Volatility & Risk

Northwest Biotherapeutics has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.

Profitability

This table compares Northwest Biotherapeutics and Evoke Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Northwest Biotherapeutics	-4,666.29%	N/A	-261.36%
Evoke Pharma	-71.32%	-308.49%	-53.66%

Insider and Institutional Ownership

0.0% of Northwest Biotherapeutics shares are owned by institutional investors. 8.7% of Northwest Biotherapeutics shares are owned by company insiders. Comparatively, 6.1% of Evoke Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Northwest Biotherapeutics and Evoke Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Northwest Biotherapeutics	$1.93 million	180.96	-$62.60 million	($0.08)	-3.31
Evoke Pharma	$8.62 million	0.82	-$7.79 million	($10.99)	-0.43

Evoke Pharma has higher revenue and earnings than Northwest Biotherapeutics. Northwest Biotherapeutics is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Evoke Pharma beats Northwest Biotherapeutics on 6 of the 11 factors compared between the two stocks.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

About Evoke Pharma

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.